Recently, two molecular subgroups of PEComas were proposed: type 1, which responds to mTOR inhibitors, and type 2, which responds to c-MET inhibitors (48). The gene discussed is MTOR; the disease is neoplasm with perivascular epithelioid cell differentiation.